BioNxt Solutions Inc. (FRA:BXT)
0.4080
+0.0280 (7.37%)
At close: Jan 30, 2026
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 11.26K CAD in the quarter ending September 30, 2025, a decrease of -34.17%. This brings the company's revenue in the last twelve months to 15.82K, down -62.34% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
15.82K CAD
Revenue Growth
-62.34%
P/S Ratio
4,789.18
Revenue / Employee
n/a
Employees
n/a
Market Cap
46.36M EUR
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
| Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
| Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
| Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
| Dec 31, 2020 | 345.65K | 137.54K | 66.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- | 1.22B |
| Nordwest Handel AG | 273.32M |
| PEH Wertpapier AG | 183.79M |
| capsensixx AG | 176.29M |
| Fernheizwerk Neukölln Aktiengesellschaft | 66.35M |
| Infas Holding AG | 63.66M |
| SBF AG | 46.20M |
| Alexanderwerk Aktiengesellschaft | 33.44M |
BioNxt Solutions News
- 6 days ago - BioNxt Solutions Inc.: BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion - Finanz Nachrichten
- 6 days ago - BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion - Wallstreet:Online
- 11 days ago - BioNxt Solutions Inc.: BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis - Finanz Nachrichten
- 11 days ago - BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS) - Wallstreet:Online
- 13 days ago - BioNxt Solutions Inc.: BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF - Finanz Nachrichten
- 13 days ago - BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF - Wallstreet:Online
- 6 weeks ago - BioNxt Solutions Inc.: Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film "Melt-in-Your-Mouth" Therapies - Finanz Nachrichten
- 6 weeks ago - Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies - Wallstreet:Online